AbCellera Biologics (ABCL) to Release Quarterly Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) will likely be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

AbCellera Biologics Price Performance

Shares of ABCL opened at $3.27 on Friday. The company has a 50-day moving average of $3.06 and a 200 day moving average of $2.83. AbCellera Biologics has a 1-year low of $2.34 and a 1-year high of $5.45. The firm has a market capitalization of $965.85 million, a price-to-earnings ratio of -5.36 and a beta of 0.42.

Analysts Set New Price Targets

ABCL has been the subject of a number of research analyst reports. KeyCorp decreased their target price on AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Benchmark reiterated a “hold” rating on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a research note on Tuesday, November 5th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.